Synthetic Lethality Exploitation by an Anti–Trop-2-Sn-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –Wild-Type Triple-Negative Breast Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-2401
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-Sn-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics

Cancer
Cancer ResearchOncology
2017English

BRCA1/2-negative Hereditary Triple-Negative Breast Cancers Exhibit BRCAness

International Journal of Cancer
Cancer ResearchOncology
2017English

Synthetic Lethal Interactions Between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

PLoS ONE
Multidisciplinary
2012English

BRCA1/2-Mutated Breast Cancer in Select EU Markets: Incidence, Treatable Populations, and Potential Market Size for Parp Inhibitors

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

PARP Inhibitors for BRCA1/2-mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions

British Journal of Cancer
Cancer ResearchOncology
2016English

mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize With PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

The Prevalence of BRCA1/2 Mutations of Triple-Negative Breast Cancer Patients in Xinjiang Multiple Ethnic Region of China

European Journal of Medical Research
Medicine
2014English

Candidate Synthetic Lethality Partners to PARP Inhibitors in the Treatment of Ovarian Clear Cell Cancer (Review)

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2017English

Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy